Abstracts tagged "B cells"

Abstract Number: 921 • 2013 ACR/ARHP Annual Meeting
Blocking The Complement Receptor 2 (CR2) Ligand-Receptor Interaction With a Novel Mouse Anti-Mouse CR2 Monoclonal Antibody Decreases Antigen-Specific Humoral Immune Responses and The Evolution Of Collagen-Induced Arthritis
Rosa Rodriguez¹, Liudmila Kulik¹, Joshua Thurman², Jonathan Hannan¹, Steve Tomlinson³ and V. Michael Holers¹, ¹Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ²Renal Division, University of Colorado School of Medicine, Aurora, CO, ³Microbiology and Immunology, Medical University of South Carolina, Charleston, NC
Background/Purpose: The CR2/CD19 complex on B cells serves as a co-receptor for membrane IgM and amplifies B cell responses through physical associations of the bound…
Abstract Number: 36 • 2013 ACR/ARHP Annual Meeting
IFN-α Induces Altered Transitional B Cell Signaling and Function In Systemic Lupus Erythematosus
Joan E. Wither¹, Nan-Hua Chang², Timothy Li³, Julie Kim⁴, Carolina Landolt-Marticorena⁵, Paul R. Fortin⁶, Dafna D. Gladman⁷ and Murray B. Urowitz⁸, ¹1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Genetics and developmental biology, Toronto Western Hospital, Toronto, ON, Canada, ⁴Toronto Western Hospital, Toronto, ON, Canada, ⁵Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁶Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Previous experiments suggest that the B cells of lupus patients are hyper-responsive to B cell receptor engagement resulting in increased tyrosine phosphorylation and Ca2+mobilization. …
Abstract Number: 1742 • 2013 ACR/ARHP Annual Meeting
Effects Of Blisibimod, An Inhibitor Of B Cell Activating Factor, On Serum Immunoglobulins and Infection Risk In Patients With Systemic Lupus Erythematosus: Observations From The Placebo-Controlled Pearl-SC and Open-Label Extension Studies
Richard A. Furie¹, Matthew Thomas², Alvina Chu³, Renee S. Martin³, Colin Hislop³ and Morton A. Scheinberg⁴, ¹The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ²Health and Research Centre, Trivandrum, Kerala, India, ³Anthera Pharmaceuticals Inc, Hayward, CA, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil
Background/Purpose: To evaluate the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on IgG, IgM and infection risk in patients…
Abstract Number: 924 • 2013 ACR/ARHP Annual Meeting
B Cell Subsets and Dysfunction Of Regulatory B Cells In IgG4-Related Diseases and Primary Sjögren Syndrome: The Similarities and Differences
Wei Lin¹, Lixia Jin², Wen Zhang¹, Hua Chen³, QingJun Wu⁴, Yunyun Fei¹, Yan Zhao¹, Xiaofeng Zeng⁵ and Fengchun Zhang³, ¹Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ²Tsinghua University, Beijing, China, ³Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Background/Purpose: IgG4 related disease (IgG4-RD) is a chronic, multisystem-involved autoimmune disease. Abnormally activated and differentiated B cells may play important roles. Regulatory B cells (Breg)…
Abstract Number: 37 • 2013 ACR/ARHP Annual Meeting
Follicular Entry Of Lymphotoxin-Expressing B Cells Via Type I Interferon Disrupts Marginal Zone Barrier Integrity and Exacerbates Systemic Autoimmunity
Hao Li¹, Hui-Chen Hsu², Qi Wu³, Jun Li³, PingAr Yang³, Yang-Xin Fu⁴ and John D. Mountz⁵, ¹Dept. Med - Immunology/Rheumatology division, University of Alabama at Birmingham, Birmingham, AL, ²Birmingham VA Medical Center, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pathology, The University of Chicago, Chicago, IL, ⁵Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Marginal zone macrophages (MZMs), a small subset of specialized splenic macrophages located in the MZ, act as final follicular entry barrier to clear apoptotic…
Abstract Number: 1743 • 2013 ACR/ARHP Annual Meeting
Administration Of AMG 557, a Human Anti-B7RP-1 (ICOSL) Antibody, Leads To The Selective Inhibition Of Anti-KLH IgG Responses In Subjects With SLE: Results Of a Phase 1 Randomized, Double-Blind, Placebo-Controlled, Sequential, Rising, Multiple-Dose Study
Barbara Sullivan¹, Wayne H. Tsuji², Vishala L. Chindalore³, Thomas D. Geppert⁴, Alla Rudinskaya⁵, Patricia Pardo⁶, Alan Kivitz⁷, C. Michael Neuwelt⁸, Meggan Mackay⁹, R. John Looney¹⁰, J. Carter Thorne¹¹, Marilee Andrew¹², Greg Arnold¹³, Michael Boedigheimer¹, Kit Chiu¹, Cherie Green¹, Arunan Kaliyaperumal¹, Christine Wang¹⁴, Andrew Welcher¹ and James Chung¹, ¹Amgen, Thousand Oaks, CA, ²Clinical Research/Inflammation, Amgen, Seattle, WA, ³Anniston Medical Clinic PC, Anniston, AL, ⁴Metroplex Clinical Research Center, LLC, Dallas, TX, ⁵Danbury Hospital, Danbury, CT, ⁶MRA Clinical Research, Miami, FL, ⁷Altoona Center for Clinical Research, Duncansville, PA, ⁸East Bay Rheumatology Research Institute, San Leandro, CA, ⁹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²Amgen, Seattle, WA, ¹³Medical Sciences, Amgen, Thousand Oaks, CA, ¹⁴Biostatistics, Amgen, Thousand Oaks, CA
Background/Purpose: The interaction of inducible costimulator (ICOS) with its ligand, B7-related protein-1 (B7RP-1 or ICOSL), plays a role in T cell differentiation, cytokine production, and…
Abstract Number: 890 • 2013 ACR/ARHP Annual Meeting
Quantitative Cell Distance Mapping In Human Nephritis Reveals Organization Of In Situ Adaptive Immune Responses
Marcus R. Clark¹, Vladimir M. Liarski¹, Natalya Kavernia², Maryellen L. Giger³, Anthony Chang⁴, Yahui Peng³ and Daniel F. Brandt², ¹Rheumatology and Knapp Center for Lupus Research, University of Chicago, Chicago, IL, ²Rheumatology, University of Chicago, Chicago, IL, ³Radiology, University of Chicago, Chicago, IL, ⁴Pathology, University of Chicago, Chicago, IL
Background/Purpose: Inflammatory infiltrates contain multiple cell types that could interact in myriad ways to amplify in situ immune responses. However, there currently are no methods…
Abstract Number: 38 • 2013 ACR/ARHP Annual Meeting
Use Of An In Vitro Whole Blood Depletion ASSAY To Compare The Efficacy Of B CELL Depleting Agents In Patients With Systemic LUPUS Erythematosus
Venkat Reddy¹, Geraldine Cambridge², D.A. Isenberg³, Mark Cragg⁴ and Maria Leandro⁵, ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴Antibody and Vaccine group, Cancer Sciences Unit, Faculty of Medicine, Southampton University, Southampton, United Kingdom, ⁵Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Variability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor…
Abstract Number: 172 • 2013 ACR/ARHP Annual Meeting
Transcript Profiling Of Kidney Biopsies From Chinese Patients With Lupus Nephritis Suggests a Prevalence Of Infiltrating CD8+ T Cells, Monocytes/Macrophages, and B Cells In ISN/RPS Class IV Disease
Zheng Liu¹, Chris Morehouse¹, Xinfang Huang², Philip Brohawn¹, Nan Shen³, Gabor G. Illei⁴, Yihong Yao¹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ³Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, cincinnati, OH, ⁴Clinical Development, MedImmune, LLC, Gaithersburg, MD
Transcript profiling of kidney biopsies from Chinese patients with lupus nephritis suggests a prevalence of infiltrating CD8+ T cells, monocytes/macrophages, and B cells in ISN/RPS…
Abstract Number: 1665 • 2013 ACR/ARHP Annual Meeting
B Cells Revisited In Giant Cell Arteritis
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Gerda Horst², Caroline Roozendaal³, Abraham Rutgers², Annemieke M.H. Boots² and Elisabeth Brouwer², ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is a primary vasculitis affecting large to medium-sized arteries. Ample evidence suggests that dendritic cells, T cells and monocytes/macrophages contribute…
Abstract Number: 705 • 2013 ACR/ARHP Annual Meeting
Treatment With Rituximab Reduces Activation Of Scleroderma Dermal Fibroblasts
Paolo Fraticelli¹, Salvatore De Vita², Nicoletta Franzolini³, Silvia Svegliati⁴, Cecilia Tonnini⁴, Barbara Gabrielli⁵, Cathryn Anne Scott⁶, Giovanni Pomponio⁷, Gianluca Moroncini⁴ and Armando Gabrielli⁴, ¹Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ²Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ³Presidio Ospedaliero di San Daniele del Friuli, ASS 4 “Medio Friuli, Udine, Italy, ⁴Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy, ⁵Università Politecnica delle Marche, Ancona, Italy, ⁶Department of Medical and Biological Sciences, Università degli studi di Udine ·, Udine, Italy, ⁷Medicina Interna, Ospedali Riuniti, Ancona, Italy
Background/Purpose: There is evidence that B lymphocytes play a role in the pathogenesis of systemic sclerosis (scleroderma). Stimulatory autoantibodies targeting PDGF receptor and activating normal…
Abstract Number: L16 • 2013 ACR/ARHP Annual Meeting
Kidney Resident B Cells and Plasmacytoid Dendritic Cells in Urine of Systemic Lupus Erythematosus patients
Eric Scott¹, Mary Anne Dooley² and Steve Clarke¹, ¹Microbiology/Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Title: Kidney resident B Cells and plasmacytoid dendritic cells (pDCs) in the urine of systemic lupus erythematosus (SLE) patients. Background/Purpose: Renal involvement remains the principal…
Abstract Number: 1629 • 2013 ACR/ARHP Annual Meeting
Functional Effect Of NR1H3 (LXRA) Promoter Polymorphisms In Korean Patients With Systemic Lupus Erythematosus
Ja-Young Jeon¹, Hyoun-Ah Kim¹, Ju-Yang Jung¹ and Chang-Hee Suh², ¹Department of Rheumatology, Ajou University School of Medicine, Suwon, South Korea, ²Department of Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose: Liver X receptor alpha (LXRA, NR1H3) and beta (LXRB, NR1H2) can influence macrophage biology by modulation of lipid metabolism and by effects on innate…
Abstract Number: 636 • 2013 ACR/ARHP Annual Meeting
Neutrophil-Mediated Interferon Activation In Systemic Lupus Erythematosus Bone Marrow
Anna Bird¹, Nida Meednu², Javier Rangel-Moreno³, Srilakshmi Yalavarthi⁴, Jennifer Barnard¹, Teresa Owen⁵, Jason S. Knight⁶, Alfred Rabinovich¹, Arumugam Palanichamy², Jane Liesveld⁷, Jason W Bauer⁸, Emily Baechler⁹, Mariana J. Kaplan¹⁰ and Jennifer H. Anolik¹¹, ¹Medicine-Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³Medicine- Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ⁴University of Michigan Rheumatology, Ann Arbor, MI, ⁵Medicine- Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ⁷Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, ⁸University of Minnesota, Minneapolis, MN, ⁹Medicine, University of Minnesota, Minneapolis, MN, ¹⁰Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD, ¹¹Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Although SLE is known to be associated with a type I interferon signature in the peripheral blood, the precise site and mechanism of IFN…
Abstract Number: 1603 • 2013 ACR/ARHP Annual Meeting
Sustained Reductions In Circulating B Cell Populations and Immunoglobulin G Levels With Long-Term Belimumab Treatment In Patients With Systemic Lupus Erythematosus
Herbert Struemper¹, William Freimuth², Christi Kleoudis³, Thi-Sau Migone⁴, David Roth³ and William Stohl⁵, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Human Genome Sciences, Inc., Rockville, MD, ³GlaxoSmithKline, King of Prussia, PA, ⁴Igenica, Burlingame, CA, ⁵Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Belimumab treatment in autoantibody-positive systemic lupus erythematosus (SLE) patients for up to 76 weeks results in sustained reduction in several circulating B cell subsets,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].